NYSEHealth CareMedical - DevicesSnapshot 2026-08-31
Reading EW? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Edwards Lifesciences grows sales about 10% a year. Profit rises with EPS near $3.00 in 2026. TAVR sales expand steadily, reaching $1.2 billion in Q1 2026. The company benefits from a rival's setback, strengthening its market position.
Growth could slow if TAVR sales falter or competition intensifies. EPS might miss guidance if costs rise. Regulatory or leadership changes could disrupt execution.
The price is about 18% above our fair value near $80. Analysts expect 11.5% revenue growth, which aligns with company guidance. Our fair value is below the Street median, reflecting a cautious view on margin and growth sustainability.
Breaks if: EPS falls below $2.95 in FY 2026
Breaks if: Revenue falls below $6.5 billion in FY 2026
Breaks if: TAVR sales growth falls below 7% in FY 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent growth. The current thesis state remains intact, supported by strong recent financial performance and management's commitment to growth targets.
The valuation is considered expensive compared to peers, reflecting a premium of 1.13 times. The market seems to have priced in a slight expectations gap, indicating that while the stock is seen as justified, there is a cautious outlook on execution quality.
Fundamentals are likely to continue on a positive trajectory, as management has consistently met growth targets in recent quarters. However, there is a moderate risk of missing expectations, especially given the recent trend of industry peers underperforming.
The long-term thesis hinges on management's ability to maintain sales growth and expand product adoption, particularly in TAVR and TMTT segments. Additionally, external factors such as sector performance and economic indicators will play a crucial role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, EW's performance and management execution appear solid for the next 1 to 3 years, but external economic conditions could impact its trajectory. Not investment advice.
